Treatment combination could improve glycemic control

A new treatment regimen may be effective in patients with poorly controlled Type 2 diabetes.

In the Phase 3 ACHIEVE-5 clinical trial, published in JAMA, researchers randomly assigned more than 500 adult patients with inadequately controlled Type 2 diabetes to receive either a combination of three, 12 or 36 milligrams of the oral, nonpeptide glucagon-like peptide-1 receptor agonist orforglipron with titrated insulin glargine or placebo once per day.

After a follow-up of 40 weeks, the researchers found that the participants who received the treatment combination, particularly those in the 12- and 36-milligram orforglipron groups, experienced greater reductions in their hemoglobulin A1c and body weight compared with the participants who received placebo. Mild to moderate gastrointestinal effects were the most common adverse events in the combination group, but there was no statistically significant increase in the risk of hypoglycemia compared with the placebo group.

Read more: JAMA

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.